Document is current
Any future updates will be listed below
-
Authors
Sato, Michio
Tanabu, Daishi
Torigoe, Daisuke
Kadomatsu, Tsuyoshi
Taniwaka, Keito
Ogata, Yoshinobu
Shiiba, Isshin
Suzuki, Yuiko
Ito, Naoki
Inatome, Ryoko
Tokuyama, Takeshi
Takeiwa, Toshihiko
Inoue, Satoshi
Kanai, Eito
Hamano, Takashi
Hirata, Hiromi
Kanamitsu, Kayoko
Kusuhara, Hiroyuki
Yokosuka, Akihito
Mimaki, Yoshihiro
Abe, Hideki
Oike, Yuichi
Yanagi, Shigeru
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science
Takeda Medical Research Foundation
Ministry of Education, Culture, Sports, Science and Technology
Japan Agency for Medical Research and Development (JP25gm2110001)
- License Information
-
More Information
Article History
Received: 8 August 2025
Accepted: 9 March 2026
First Online: 20 March 2026
Competing interests
: K.T. and S.Y. are board members and shareholders of MitoGenic Co., Ltd. (Tokyo, Japan), and the company has a pending PCT patent application related to berberrubine-based compounds (PCT/JP2024/032131) and holds the registered trademark “MitoRubin” in Japan. All other authors declare no competing interests.
